Literature DB >> 17197014

Persistent exercise attenuates nicotine- but not clonidine-induced antinociception in female rats.

Wendy Foulds Mathes1, Robin B Kanarek.   

Abstract

Exercise decreases the antinociceptive effects of opiate drugs. It has been hypothesized that the exercise-induced attenuation of opiate drug action is the result of the development of cross-tolerance between endogenous opioids released during exercise and exogenous opiates. The present study was designed to evaluate the role of exercise on non-opiate antinociception. Female Long-Evans rats were allowed ad lib access to running wheels. After 3 weeks, antinociceptive responses of animals were measured using the tail flick test following the administration of clonidine or nicotine. Nicotine and clonidine both produced dose-dependent increases in antinociceptive responses. Active animals were significantly less sensitive to nicotine-induced antinociception than inactive animals. There was no difference between the two groups in clonidine-induced antinociception. The results of these experiments suggest that exercise does not attenuate non-opioid, clonidine-induced antinociception. However, exercise does attenuate nicotine-induced antinociception. Therefore, the effect of persistent exercise on analgesic drugs is not specific to opiates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17197014      PMCID: PMC1945163          DOI: 10.1016/j.pbb.2006.11.011

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  42 in total

1.  Kappa-opioid receptor modulation of nicotine-induced behaviour.

Authors:  B Hahn; I P Stolerman; M Shoaib
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

2.  The development of cross-tolerance between morphine and nicotine in mice.

Authors:  M R Zarrindast; M R Khoshayand; B Shafaghi
Journal:  Eur Neuropsychopharmacol       Date:  1999-03       Impact factor: 4.600

3.  Activation of alpha2-adrenoceptors in the trigeminal region produces sex-specific modulation of nociception in the rat.

Authors:  S Nag; S S Mokha
Journal:  Neuroscience       Date:  2006-08-23       Impact factor: 3.590

Review 4.  Transmitters involved in antinociception in the spinal cord.

Authors:  S Fürst
Journal:  Brain Res Bull       Date:  1999-01-15       Impact factor: 4.077

5.  Monoamine oxidase A activity and norepinephrine level in hippocampus determine hyperwheel running in SPORTS rats.

Authors:  Masaki Morishima; Nagakatsu Harada; Sayuri Hara; Atsuko Sano; Hiromasa Seno; Akira Takahashi; Yusuke Morita; Yutaka Nakaya
Journal:  Neuropsychopharmacology       Date:  2006-01-18       Impact factor: 7.853

6.  The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model.

Authors:  M I Damaj; E M Meyer; B R Martin
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

7.  Long-term voluntary access to running wheels decreases kappa-opioid antinociception.

Authors:  K E D'Anci; A V Gerstein; R B Kanarek
Journal:  Pharmacol Biochem Behav       Date:  2000-06       Impact factor: 3.533

8.  Effects of repeated nicotine administration and footshock stress on rat mesoprefrontal dopamine systems: Evidence for opioid mechanisms.

Authors:  T P George; C D Verrico; L Xu; R H Roth
Journal:  Neuropsychopharmacology       Date:  2000-07       Impact factor: 7.853

9.  Sex differences in cocaine- and nicotine-induced antinociception in the rat.

Authors:  R M Craft; R B Milholland
Journal:  Brain Res       Date:  1998-10-26       Impact factor: 3.252

10.  A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse.

Authors:  G Tanda; G Di Chiara
Journal:  Eur J Neurosci       Date:  1998-03       Impact factor: 3.386

View more
  1 in total

1.  Running and addiction: precipitated withdrawal in a rat model of activity-based anorexia.

Authors:  Robin B Kanarek; Kristen E D'Anci; Nicole Jurdak; Wendy Foulds Mathes
Journal:  Behav Neurosci       Date:  2009-08       Impact factor: 1.912

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.